EssexBio

Essex-Bio Group

简繁 EN

ANNOUNCEMENTS & SHAREHOLDER INFORMATION

Normative Disclosure, Honest Communication

Select category

ANNOUNCEMENTS SHAREHOLDER INFORMATION

Select time

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012

Date

Title

File

Times

2026-06-25

NEXT DAY DISCLOSURE RETURN

8

2026-06-24

NEXT DAY DISCLOSURE RETURN

19

2026-06-23

NEXT DAY DISCLOSURE RETURN

29

2026-06-22

NEXT DAY DISCLOSURE RETURN

36

2026-06-18

NEXT DAY DISCLOSURE RETURN

87

2026-06-16

INSIDE INFORMATION STUDY PRIMARY ENDPOINT MET IN AURA-2, A PHASE 3 CLINICAL STUDY IN RELATION TO THE CO-DEVELOPMENT OF THE LICENSED PRODUCT WITH HENLIUS FOR THE TREATMENT OF EXUDATIVE (WET) AGE-RELATED MACULAR DEGENERATION

100

2026-06-02

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2026

171

2026-05-26

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 26 MAY 2026

195

2026-05-04

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2026

311

2026-04-01

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2026

545

2026-03-31

NOTICE OF ANNUAL GENERAL MEETING

541

2026-03-31

FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON TUESDAY, 26 MAY 2026 (or any adjournment thereof)

512

2026-03-31

PROPOSALS FOR GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES, RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING

488

2026-03-23

FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2025

500

2026-03-23

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025

597

2026-03-11

NOTICE OF BOARD MEETING

651

2026-03-03

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2026

662

2026-02-03

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2026

879

2026-01-15

VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE IN RELATION TO EXCLUSIVE DISTRIBUTION AGREEMENT WITH OSTEOPORE

1068

2026-01-09

INSIDE INFORMATION APPROVAL TO COMMERCIALISE MULTI-DOSE SODIUM HYALURONATE EYE DROPS (0.3%) IN THE PRC

1065

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT